Newamsterdam Pharma Company Nv stock is traded at $18.89, with a volume of 1,563,291. It is down -9.75% in the last 24 hours and down -17.15% over the past month. NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Previous Close:
$20.93
Open:
$20.77
24h Volume:
1,563,291
Relative Volume:
0.92
Market Cap:
$2.27B
Revenue:
$22.57M
Net Income/Loss:
-$212.73M
P/E Ratio:
-
EPS:
-$1.80
Net Cash Flow:
-$142.19M
1W Performance:
-9.01%
1M Performance:
-17.15%
6M Performance:
-36.72%
1Y Performance:
-50.45%
1-Day Range:
$18.86$20.77
1-Week Range:
$18.86$22.26
52-Week Range:
$18.86$42.21
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Name
Newamsterdam Pharma Company NvSector
HealthcareIndustry
BiotechnologyPhone
35 206 2971Address
GOOIMEER 2-35, NARRDEN, NetherlandsMarket Cap
Revenue
Net Income
Cash Flow
EPS